



To: Carter BloodCare Customers
From: Hospital Relations Department
Date: August 30, 2022
Re: Updated Circular of Information

On May 24, 2022, the FDA issued guidance document “Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Components” to blood establishments that collect blood and blood components. This guidance supersedes the guidance of the same title dated April 2020 and updated August 2020. This guidance removed the recommendations to indefinitely defer blood donors for: 1) geographic risk of possible exposure to bovine spongiform encephalopathy for time spent in the United Kingdom (U.K.) from 1980-1996 and for time spent in France and Ireland from 1980-2001, and 2) receipt of a blood transfusion in the U.K., France, and Ireland from 1980-present. The guidance also provides recommendations for requalification of individuals previously deferred for these geographic risk factors provided they meet all other eligibility requirements.

Please see the updated electronic version of the Circular of Information. Hard copies are also available through the distribution department. This version includes wording related to the updates made to CJD and vCJD guidance for industry.

The electronic version can be accessed and viewed at the following link:

Direct link: [Circular of Information Carter BloodCare](#) or by visiting <https://www.cbcspecialtyservices.org> and then click on [Licenses & Accreditations](#).